Transcranial Magnetic Stimulator Market Worth USD 1,732.11 Million By 2026

The global transcranial magnetic stimulator market is anticipated to reach USD 1,732.11 million by 2026, according to a new report by Grand View Research, Inc. Increasing incidence of psychological and neurological disorder such as major depressive disorder is anticipated to boost the market growth.

Increasing number of patients suffering from depression and other neurological disorder are driving the market growth. For instance, according to the National Institute of Mental Health (NIMH), around 17.3 million people in the U.S. have at least one major depressive disorder. Other neurological disorder such as schizophrenia which is a severe mental disorder start between the ages of 16-30 years. According to National Institute of Mental Health (NIMH), 49.0% people died through schizophrenia.

Increasing number of devices receiving regulatory approvals are anticipated to increase the market for new and advanced stimulators. For instance, in 2018, Brainsway received FDA approval for dTMS device for the treatment of Obsessive-Compulsive Disorder (OCD). In addition, increasing awareness programs by the various NGOs and associations will drive the market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/transcranial-magnetic-stimulator-market

Further key findings from the study suggest:

The Repetitive Transcranial Magnetic Stimulation System (rTMS) segment dominated the market in 2018. This is attributed to the increasing number of patients suffering from neurological disorders and Obsessive-Compulsive Disorder (OCD).
One of the major growing application is depression which is a mental disorder. TMS is considered appropriate therapy for the treatment of depression, mainly for those who have failed to achieve the satisfactorily treatment through antidepressant medication. According to WHO, in 2018, more than 300 million people are affected by the depression. It’s a leading cause of disability in the U.S population.
North America dominated the TMS market with the highest revenue share in 2018 owing to the increasing number of cases such as Alzheimer’s and Parkinson’s disease and increasing disposable income of individuals.
Some of the key players operating in the market are BrainsWay, MagStim, Nexstim, MagVenture and Eneura. Key players are introducing technologically enhanced products to gain a competitive advantage in the industry. For instance, in May 2019, MagStim received FDA approval for Horizon Stimguide TMS navigation system designed to provide precise and consistent coil positioning during treatment for major depressive disorders.

Uveitis Treatment Market Worth $765.31 Million By 2026

The global uveitis treatment market size is expected to reach USD 765.31 million by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 5.8% during the forecast period. Rising prevalence of the condition is anticipated to drive the growth. For instance, according to The Ocular Immunology and Uveitis Foundation, around 43,000 new eye inflammation cases are being diagnosed each year in U.S.

Eye inflammation is also very prevalent among children. However, majority of the affected population ranges from 20 to 50 years of age. Growing geriatric population is also an important factor driving the growth of the market. Rise in number of R&D activities aiming at new drug development is another attribute increasing the demand for these treatments.

For instance, ADX-102 Ophthalmic Solution, by Aldeyra Therapeutics, Inc. is in Phase 2 clinical trial for the treatment of noninfectious anterior uveitis. The National Eye Institute is also engaged in conducting and supporting various research studies in this field. Increasing prevalence of infectious diseases is another contributing factor to the market growth. Infectious uveitis surrounds a significant array of potential pathogens, which is likely to pose immense threat to the people affected.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/uveitis-treatment-market

Further key findings from the report suggest:

Corticosteroids led the market in 2018 owing to its wide application for treating noninfectious uveitis as well as availability of varied corticosteroids drugs
Monoclonal antibodies are expected to exhibit lucrative CAGR over the forecast period due to rising development of novel biologic drugs
Anterior held the largest market share in 2018 owing to growing prevalence and tendency of recurrence of anterior uveitis
Posterior is anticipated to showcase lucrative growth over the forecast period owing to rise in the number of R&D and clinical trials undergoing for the treatment posterior uveitis
Noninfectious segment held significant revenue share in 2018 owing to the wide array of treatment methods coupled with rising cases of the condition
Infectious segment is gaining traction in the uveitis treatment market owing to rising prevalence of infectious diseases
North America held the largest revenue share in 2018 owing to increasing prevalence of noninfectious uveitis as well as rising healthcare expenditure in this region
Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the rising number of infectious diseases in the developing countries
Few major companies are Allergan, Inc.; Valeant Pharmaceutical International, Inc.; Eyegate Pharmaceuticals, Inc.; AbbVie Inc.; Regeneron Pharmaceuticals, Inc; and Santen Pharmaceutical Co., Ltd

Elastography Imaging Market Worth $3.5 Billion By 2026

The global elastography imaging market size is expected to reach USD 3.5 billion by the end of 2026, according to a new report by Grand View Research, Inc., registering a 7.8% CAGR over the forecast period. Increasing incidence of breast cancer and chronic liver disorders is expected to significantly drive the market. Additionally, increasing demand for minimally-invasive procedures and ongoing studies to assess the potential applications of elastography are factors expected to contribute toward rapid growth.

Currently elastography has wide applications in assessing breasts, thyroid, prostate, and liver. Increasing number of ongoing studies are expected to increase its applications in diagnosis of various conditions such neurodegenerative disorders and chronic kidney diseases. It has shown promising results for its use in assessment of kidney health during and after transplantation.

North America dominated the market in 2018 and is expected to continue its dominance during the forecast period. The elastography imaging market growth observed in the region is due to the presence of a large number of global players, along with high adoption rate for advanced imaging techniques.

Growing strategic alliances among players for development and distribution of products is expected to propel the market during the forecast period. Moreover, development of new surgical centers in different locations will increase the adoption of advanced imaging systems.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/elastography-imaging-market

Further key findings from the report suggest:

In 2018, non-cold chain logistics held the largest market share in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control
Cold chain logistics segment is expected to register the faster CAGR over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits
Warehousing and storage held the largest market share among the types of services in 2018
Asia pacific expected to emerge with the fastest CAGR over the forecast period owing to adoption of medicines from aging population and shift of drug sales from brand manufacturers to generic
Key players operating in the biopharmaceutical third party logistics market include DHL International GmbH., SF Express, United Parcel Service of America, Inc, AmerisourceBergen Corporation, DB Schenker, Kuehne and Nagel, Kerry logistics network limited and AgilityBy modality, the ultrasound segment is predicted to register significant growth during the forecast period owing to advantages such as low price, accessibility, and high degree of measurement for tissue deformation
On the basis of end use, the hospital segment is anticipated to hold the largest share in the market during the forecast period due to rising number of ultrasound and MRI-based elastography procedures and growing trends of hospital-based imaging facilities
By way of application, the radiology domain is predicted to hold a large share in the market over the forecast period owing to increase in demand in image-guided radiotherapy and radiology ultrasound
Asia Pacific is anticipated to witness lucrative growth during the forecast period due to improving healthcare facilities and rising geriatric population who are prone to developing targeted disorders
Major players in the elastography imaging industry are focusing on growth strategies such as partnerships, collaborations, mergers, and acquisitions. Some of the leading players are Esaote SpA; Canon Medical Systems Corporation; Koninklijke Philips N.V.; Hitachi, Ltd.; GE Healthcare; Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthineers; Toshiba America Medical Systems, Inc.; and Samsung Medison Co., Ltd.

Ophthalmic Knife Market Size Worth $2.4 Billion By 2026

The global ophthalmic knives market size is expected to reach USD 2.4 Billion by 2026, as per a new report by Grand View Research Inc. It is projected to register a CAGR of 4.9% during the forecast period. Introduction of advanced knives and rising incidence of age related ophthalmic diseases are some of the major factors driving the growth.

Increasing overall life expectancy and rising geriatric population is expected to cause steep increase in age related ophthalmic disorders. Along with these, incidence of lifestyle associated ophthalmic devices including myopia and hypermetropia are expected showcase significant growth during the forecast period. Most of these ophthalmic conditions cannot be treated by drugs. Increasing number of ophthalmic surgeries are expected to boost the market during forecast period.

High competition and introduction of local players are the factors encouraging market players to introduce advanced knives at affordable prices. Major players are focusing on developing innovative manufacturing techniques along with advanced raw materials to reduce the device price.

Incorporation of new reimbursement policies in developed countries along with growing efforts of non-profit organizations to increase awareness about ophthalmic conditions and to provide affordable/free ophthalmic procedures in rural regions are the factors expected to boost the number of ophthalmic surgeries.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/ophthalmic-knives-market

Further key findings from the report suggest:

North America captured the largest ophthalmic knife industry share in 2018 owing to favorable reimbursement policies, presence of major market players, and rise in geriatric population
Straight knives segment is anticipated to expand at a CAGR of 4.10% during the forecast period owing to fine design, durability, and sharpness of the knives
Slit knives segment is also expected to register lucrative CAGR in near future owing to extensive use for entry in anterior chamber/phaco stab incision (single bevel) in eye-related surgeries
Single-use/disposable knives segment is expected to witness significant growth over the forecast period due to features such as safety and affordability
The key players profiled in the ophthalmic knife market comprise Alcon, Inc.; Hoya Corporation; Essilor; Topcon Corporation; Hai Laboratories, Inc.; Bausch and Lomb Incorporated; MANI Inc.; Seiko Optical Products Co., Ltd.; Nidek Co., Ltd.; Ziemer Group; Alltion; and DGH Technology

Surgical Blades Market Worth $181.20 Million By 2026

The global surgical blade market size is anticipated to reach USD 181.2 million by 2026, as per a new report by Grand View Research, Inc., exhibiting a CAGR of 3.6% over the forecast period. Increase in surgeries due to increase in number of accidents, coupled with a growing geriatric population prone to various disorders, is currently driving the market. Moreover, increase in number of surgeons at a global scale is also propelling the demand for surgical blades.

Several key players are investing in R&D to launch new and innovative products. Increase in individual disposable income & standard of living, and growth in awareness regarding modern surgical procedures are other factors increasing the number of medical procedures. Increase in trauma cases and other disorders, such as cancer, which require surgery, is further augmenting demand for surgical blades. Furthermore, availability of these blades in various shapes and sizes for surgical intervention in multiple illnesses is driving the overall market.

With a wide range of procedures in healthcare, more patients are willing to undergo new treatments due to improving affordability and feasibility. Stainless steel blades are increasingly preferred due to features such as cleaner incisions, superior cutting, and numbering of scalpel handles. Being low-risk medical tools, these products do not need strict regulatory processes, which encourages and eases product launches.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/surgical-blades-market

Further key findings from the report suggest:

Surgical blades come in a variety of forms, enabling surgeons and medical staff to choose the right blade for a medical procedure
By product, stainless steel blades are expected to lead market over the forecast period, due to better anti-corrosion properties. They are more suitable for procedures involving large volumes of saline solution and multiple incisions
By material, sterile blades are expected to dominate the market since they can provide a sharp cutting edge for high efficiency, enabling cleaner incisions and superior cutting
By end use, hospitals segment accounted for a share of over 40.0% and is expected to grow at a CAGR of 3.7% over the forecast period
Some key players of surgical blades market are Swann-Morton Limited; PL Medical Co.; Hill-Rom, LLC; Beaver-Visitec International; VOGT Medical; Hu-Friedy Mfg. Co., LLC; B. Braun Melsungen AG; and Surgical Specialties Corporation.

Plastic Surgery Instruments Market Size Worth $1.9 Billion By 2026

The global plastic surgery instruments market size is expected to reach USD 1.9 billion by 2026, according to a new report by Grand View Research, Inc, exhibiting a CAGR of 8.8%. Increasing number of surgical procedures coupled with technological advancements is anticipated to drive the market. Moreover, increasing awareness about plastic or reconstructive surgeries and improving affordability of related healthcare services are expected to aid growth over the forecast period.

Several key players are investing on R&D to launch innovative products. Moreover, rise in disposable income, improvement of standard of living, high social media influence, and increase in awareness among people are some of the factors boosting the number of surgical procedures. Plastic and reconstructive surgeries are performed mainly to restore tissue function and improve the body’s appearance caused by trauma, burns, birth disorders, or any other disease.

According to WHO, 10 million people are injured or disabled due to road accidents every year, leading to extensive wound surgeries. This is expected to increase the number of plastic surgeries. The number of breast augmentation procedures has also increased by 4.3%, from 313,735 procedures in 2018 to 300,378 procedures in 2017. In addition, women with implants are also required to undergo additional surgeries due to complications such as leakage, scars, or shift of implants. High cost of implants coupled with rising demand is propelling demand for surgical instruments for breast procedures, thereby driving the overall market. Moreover, with rising healthcare expenditure in emerging economies, the number of plastic and cosmetic surgeries has increased to enhance aesthetic appeal, thus driving growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/plastic-surgery-instruments-market

Further key findings from the study suggest:

North America accounted for largest share owing to favorable reimbursement policies, presence of key local market players, and government initiatives
Asian countries are estimated to show the highest growth rate of over 12%, due to rising technological advancements, increasing investments, improving reimbursement scenario, and growing medical tourism
Handheld surgical instruments dominated the products segment with over 70% share in 2018 driven by easy availability and high use of these instruments in invasive and minimally invasive surgeries
Some of the key companies of plastic surgery instruments market are Sklar Surgical Instruments; Zimmer Biomet holdings, Inc.; B. Braun Melsungen AG; Blink Medical Ltd.; Bolton Surgical Ltd.; Integra Life Sciences; Karlz Storz; and Anthony Product, Inc.

Biopharmaceutical 3PL Market Size Worth $120.64 Billion By 2025

The global biopharmaceutical third party logistics market size is expected to reach USD 120.64 billion by 2025, at a CAGR 4.9% over the forecast period, according to a new report by Grand View Research, Inc. The market for biopharmaceutical third party logistics (3PL) is majorly driven by rising demand for temperature controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales. Rising adoption of automated storage and retrieval systems in the emerging countries is an ongoing trend in the pharmaceutical logistics companies that has gained a significant traction.

Furthermore, the trend of shifting from small molecule drugs to biopharmaceuticals, mainly vaccines and biologics, is projected to drive the market. Since, these small molecule drugs are temperature sensitive products, demand for temperature controlled transportation and storage increases and thus is responsible for the market growth. As of now, the pharmaceutical sales through distributors have grown from USD 304.6 billion in 2013 to USD 440.2 billion in 2016. However, the average number of manufacturers per distributor had declined from 1,474 in 2014 to 1,211 in 2016. This data depicts that there is an increase in quantity of pharmaceutical products being distributed, and thus, is expected to surge the demand for 3PL services.

Additionally, environmental concerns and cost have caused a slight shift in the means of transport used for commercial product, moving from airway to seaway shipping and in roadways from truck to intermodal (both rail and truck). The intermodal transport is majorly used by these pharmaceutical companies to reduce the carbon footprint. The ongoing trend shows that the pharmaceutical manufacturers have shifted towards sea freight to reduce the cost and risk factor. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-third-party-logistics-3pl-market

Further key findings from the report suggest:

In 2018, non-cold chain logistics held the largest market share in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control
Cold chain logistics segment is expected to register the faster CAGR over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits
Warehousing and storage held the largest market share among the types of services in 2018
Asia pacific expected to emerge with the fastest CAGR over the forecast period owing to adoption of medicines from aging population and shift of drug sales from brand manufacturers to generic
Key players operating in the biopharmaceutical third party logistics market include DHL International GmbH., SF Express, United Parcel Service of America, Inc, AmerisourceBergen Corporation, DB Schenker, Kuehne and Nagel, Kerry logistics network limited and Agility

Healthcare Reimbursement Market Size Worth $20.46 Trillion By 2026

The global healthcare reimbursement market size is expected to reach USD 20.45 trillion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 19.0% during the forecast period. Supportive government initiatives along with rising cost of prescription medicines are likely to work in favor of the market.

Hospital, Human Heart, Medical Exam, Pharmacy, Currency

The U.S. Affordable Care Act focuses on controlling and minimizing costs of healthcare. The law supports innovative methods to deliver medical care to reduce healthcare costs and makes affordable health insurance available to more people. Since the Obamacare came into effect in 2014, the number of uninsured children under the age of 18 in the U.S. reduced to 5.0% in 2015 as compared to 9% in 2008.

In addition, the Centre for Medicare & Medicaid Services is working towards delivery of reliable high-quality care, endorsement of efficient results in healthcare system, and making health insurance affordable for millions of Americans who are seeking and getting coverage. The Medicaid spending in the U.S. grew by 3.9% in 2016 or 17.0% of the total National Health Expenditure. And Medicare spending grew by 3.6% in 2016 or 20.0% of the total National Health Expenditure.

The underpaid segment is anticipated to dominate the market through 2026 owing to growing cases of frauds against government healthcare programs and increasing use of healthcare services that are not medically required. There have been several cases where businesses and individuals have defrauded federal and state government healthcare programs by submitting false claims for healthcare services, treatment, pharmaceutical, and medical devices that were never rendered.

Also, the rivalry among healthcare providers and rising pressure from commercial and public payers to reduce costs as well as to improve care are shifting their focus towards value-based care models from volume-based healthcare models.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/healthcare-reimbursement-market

Further Key Findings From the Study Suggest:

Underpaid emerged as the largest segment in 2017 owing to increasing number of insurance plans that do not cover full reimbursement
On the basis of payers, private players accounted for the leading share in the market in 2017 owing to presence of a large number of private players
North America dominated the market in 2017. A raft of insurance players and strong reimbursement framework are facilitating the dominance of the region
The market in Asia Pacific is projected to witness rapid growth during the forecast period owing to rising penetration of insurance services in rural and urban areas
Some of the market players are UnitedHealth Group, Allianz, Aviva, Aetna, Nippon Life Insurance, CVS Health, WellCare Health Plans, BNP Paribas, The Blue Cross Blue Shield Association, and AgileHealthInsurance.

Artificial Intelligence In Healthcare Market Worth $31.3 Billion By 2025

The global artificial intelligence in healthcare market size is expected to reach USD 31.3 billion by 2025, growing at a CAGR 41.5% over a forecast period, according to a new report by Grand View Research, Inc. The rising demand to reduce healthcare costs, increasing adoption of precision medicine, growing importance of big data in healthcare, and declining hardware costs are some factors propelling adoption of AI technology in healthcare industry. Moreover, rise in potential applications of AI-based tools in medical care and growth in venture capital investments are anticipated to aid growth over the forecast period.

Rise in the number of cross-industry collaborations is anticipated to fuel growth. For instance, in March 2018,Microsoft announced partnership with Apollo Hospitals, one of the prominent healthcare systems in India. The partnership was focused on developing and deploying new machine learning models for predicting the risk of developing cardiac diseases and aid doctors in treatment planning. Increase in venture capital funding is a key factor propelling growth of AI start-ups, which is further contributing to market growth.

The adoption of AI in healthcare is increasing, as healthcare providers are focused on enhancing patient care further. The adoption of this technology in healthcare has various benefits, both patients and healthcare providers. AI enables personalized care, based on body constitution and past medical history. Moreover, the shortage of physicians in some countries is anticipated to increase demand for AI in healthcare.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market

Further key findings from the study suggest:

In 2018, software solutions held the largest revenue share owing to the development of AI-based software solutions for the healthcare sector
Clinical trials held the largest revenue share in 2018, and this can be attributed to the growing focus of pharmaceutical companies on incorporating AI in automation of clinical trial processes.
North America held the largest revenue share, owing to high adoption of healthcare IT solutions in the region and availability of well-established healthcare infrastructure
Asia Pacific is expected to exhibit the fastest CAGR over the forecast period, owing to growing AI-based start-ups, improving healthcare IT infrastructure, and increasing adoption of advanced technologies.
Some key players are IBM Corporation; NVIDIA Corporation, Nuance Communications, Inc.; Microsoft; Intel Corporation; and DeepMind Technologies Limited

Myasthenia Gravis Treatment Market Size Worth $2.06 Billion By 2026

The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to a new report by Grand View Research. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/myasthenia-gravis-mg-treatment-market

Further Key Findings From the Study Suggest:

Medications are expected to obtain the largest market share in the treatment segment. This can be attributed to the high adoption of immunotherapies and the recent approval of promising drugs.
Currently, no cure is available for myasthenia gravis, however patients can be treated with medications and surgery for the management of the symptoms.
North America is likely to dominate the MG treatment market due high healthcare expenditure and favorable reimbursement scenario
The Asia Pacific region is expected to grow at the highest CAGR over the forecast period due to improving healthcare infrastructure and increasing disposable income in the region.
Some of the major companies operating in the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc.